Abstract |
The effects of BRL 26921, an active-site acylated streptokinase-plasminogen complex, on the fibrinolytic and coagulation systems were studied in 13 patients treated for acute myocardial infarction with a short intravenous infusion of 30 mg of the new drug. In 12/13 patients (92%) significant changes were observed in the concentrations of fibrinogen, fibrin( ogen) degradation products, plasminogen, alpha 2-antiplasmin and F VIII:C; all changes indicating a substantial degree of systemic fibrinolysis. In only one patient were no signs of systemic activation of the fibrinolytic system observed. The therapeutic efficacy of the drug was 85% in this study.
|
Authors | J J Hoffmann, F J Van Rey, J J Bonnier |
Journal | Thrombosis research
(Thromb Res)
Vol. 37
Issue 5
Pg. 567-72
(Mar 01 1985)
ISSN: 0049-3848 [Print] United States |
PMID | 3920779
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Fibrin Fibrinogen Degradation Products
- Fibrinolytic Agents
- alpha-2-Antiplasmin
- Anistreplase
- Factor VIII
- Fibrinogen
- Plasminogen
- Streptokinase
|
Topics |
- Adult
- Aged
- Anistreplase
- Factor VIII
(analysis)
- Female
- Fibrin Fibrinogen Degradation Products
(analysis)
- Fibrinogen
(analysis)
- Fibrinolytic Agents
(therapeutic use)
- Humans
- Male
- Middle Aged
- Myocardial Infarction
(drug therapy)
- Plasminogen
(therapeutic use)
- Streptokinase
(therapeutic use)
- alpha-2-Antiplasmin
(analysis)
|